Ergoteles’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Ergoteles’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,780	Closed	-$148K	–	1273
2023 Q1	$148K	Buy	+13,780	New	+$182K	0.01%	1064

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Ergoteles's KNSA Position: Q2 2023 in Review

Ergoteles sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2023, closing a stake of 13,780 shares — an estimated $148K sold.

Ergoteles first reported a position in KNSA in Q1 2023 and held it in 1 quarter. The position peaked at $148K in Q1 2023. 127 funds tracked by Wall St. Rank hold KNSA as of Q2 2023.

Ergoteles reported no remaining Kiniksa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 13,780 Kiniksa Pharmaceuticals shares in Q2 2023, an estimated $148K.
Ergoteles first reported a position in Kiniksa Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Ergoteles's Kiniksa Pharmaceuticals position peaked at $148K in Q1 2023.
127 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.